Recombinant LAG3 (Relatlimab Biosimilar) anticorps

N° du produit ABIN7795123

Cet anticorps anti-LAG3 (Relatlimab Biosimilar) est un anticorps Souris Monoclonal détectant LAG3 (Relatlimab Biosimilar) dans FACS et in vivo. Adapté pour Humain.

Aperçu rapide pour Recombinant LAG3 (Relatlimab Biosimilar) anticorps (ABIN7795123)

Antigène: LAG3 (Relatlimab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp LAG3 (Relatlimab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité: Research Grade

Détail du produit anti-LAG3 (Relatlimab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Relatlimab Biosimilar, Human LAG-3 Monoclonal Antibody

Attributs du produit: What is relatlimab biosimilar research grade? Relatlimab Biosimilar uses the same protein sequences as the therapeutic antibody relatlimab. Relatlimab is a lymphocyte-activation gene 3 (LAG-3)-blocking antibody that is being investigated with other agents in a variety of tumor types. LAG-3 is a cell-surface molecule found on effector T cells and regulatory T cells, and it works to control T cell response, activation, and growth. Preclinical studies suggest that inhibiting LAG-3 could restore effector function of exhausted T cells and could potentially promote an anti-tumor response. LAG-3 is a component of an immune checkpoint pathway that inhibits T-cell activity. Relatlimab, a human IgG4 LAG-3-blocking antibody, restores the effector function of exhausted T cells, reinvigorating T cells to attack cancer. Relatlimab and the anti-PD-1 agent nivolumab modulate potentially synergistic immune checkpoint pathways and can enhance antitumor immune responses. The two-drug combination has a generally manageable safety profile and can trigger durable tumor regressions in patients with melanoma whose disease has progressed after anti-PD-1 monotherapy.

Purification: Protein A or G affinity column

Pureté: >95 % by reducing SDS-PAGE

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method

Immunogène: Human LAG-3

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: > 3 mg/mL

Stock: 4 °C,-20 °C

Stockage commentaire: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Détails sur LAG3 (Relatlimab Biosimilar)

Antigène: LAG3 (Relatlimab Biosimilar)

Autre désignation: Relatlimab Biosimilar

Classe de substances: Biosimilar